Related references
Note: Only part of the references are listed.A Real-Life One-Year Non-Interventional Study Assessing Safety, Tolerability, and Treatment Outcome of the SQ HDM SLIT-Tablet (Acarizax(R)) in House Dust Mite Allergic Rhinitis With or Without Asthma
Kirsten Sidenius et al.
PULMONARY THERAPY (2021)
The need for clean air: The way air pollution and climate change affect allergic rhinitis and asthma
Ibon Eguiluz-Gracia et al.
ALLERGY (2020)
Acute systemic reactions to sublingual immunotherapy for house dust mite
Nicky S. Janssens et al.
ALLERGY (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy
Boudewijn J. H. Dierick et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2020)
EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma
Ioana Agache et al.
ALLERGY (2019)
The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease
Waltraud Emminger et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2017)
Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma A Randomized Clinical Trial
J. Christian Virchow et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial
Pascal Demoly et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Epigram study: Terms of use and safety of Grazax® treatment in real-life settings obtained from a random sample of French clinicians who are qualified in allergy
J. -F. Fontaine et al.
REVUE FRANCAISE D ALLERGOLOGIE (2016)
Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber
Hendrik Nolte et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial
Holger Mosbech et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Validation of a self-questionnaire for assessing the control of allergic rhinitis
P. Demoly et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2011)
Specific sublingual Immunotherapy: ODISSEE after one year Preliminary results of ODISSEE (observatory of the indication and management of respiratory allergies -rhinitis and/or conjunctivitis and/or allergic asthma- by specific sublingual immunotherapy)
A. Didier et al.
REVUE FRANCAISE D ALLERGOLOGIE (2011)
Grazax (R) - Safety of specific immunotherapy with tablets taken at home
A. Magnan et al.
REVUE FRANCAISE D ALLERGOLOGIE (2010)
A Population-based Clinical Study of Allergic and Non-allergic Asthma
Thomas Bllingtoft Knudsen et al.
JOURNAL OF ASTHMA (2009)
Rhinitis and onset of asthma: a longitudinal population-based study
Rafea Shaaban et al.
LANCET (2008)
Risk factors of frequent exacerbations in difficult-to-treat asthma
A ten Brinke et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study
J Sunyer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Prevalence and rate of diagnosis of allergic rhinitis in Europe
V Bauchau et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
The link between allergic rhinitis and allergic asthma: A prospective population-based study. The Copenhagen Allergy Study
A Linneberg et al.
ALLERGY (2002)
Share Paper
